Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Cash from Investing Activities (2018 - 2025)

BioNexus Gene Lab's Cash from Investing Activities history spans 8 years, with the latest figure at $994646.0 for Q3 2025.

  • For Q3 2025, Cash from Investing Activities rose 589.59% year-over-year to $994646.0; the TTM value through Sep 2025 reached $1.5 million, up 196.37%, while the annual FY2024 figure was $418202.0, 123.31% up from the prior year.
  • Cash from Investing Activities for Q3 2025 was $994646.0 at BioNexus Gene Lab, up from -$28532.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $994646.0 in Q3 2025 and bottomed at -$1.4 million in Q4 2023.
  • The 5-year median for Cash from Investing Activities is -$49903.0 (2022), against an average of -$71926.5.
  • The largest annual shift saw Cash from Investing Activities plummeted 2756.3% in 2023 before it skyrocketed 2170.31% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$76289.0 in 2021, then skyrocketed by 34.59% to -$49903.0 in 2022, then tumbled by 2756.3% to -$1.4 million in 2023, then surged by 138.9% to $554402.0 in 2024, then skyrocketed by 79.41% to $994646.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Cash from Investing Activities are $994646.0 (Q3 2025), -$28532.0 (Q2 2025), and -$15646.0 (Q1 2025).